European Pharmaceutical Review

MARCH 9, 2023

1 These substances “are pharmacologically and biologically active at low doses,” Dr Kishore Hotha, Global Head of Analytical Research & Development at Veranova, explained. ” Highly potent APIs are pharmacologically and biologically active compounds at low doses. What training is required for employees to handle HPAPIs safely?

Safety 89

Safety Pharmacology Training Manufacturing 89

pharmaphorum

JANUARY 17, 2023

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech Elicio Therapeutics. Darrell Irvine.

Pharmacology 68

Pharmacology Engineering Consulting Leads 68

European Pharmaceutical Review

FEBRUARY 14, 2024

Firstly, the pharmacological response to LBPs does not follow traditional pharmacokinetic principles. LBP drug substance production considerations Lead candidate strains are often isolated from healthy human subjects to establish a master cell bank (MCB).

Food and Drug Administration 75

Food and Drug Administration Manufacturing Engineering Pharmacology 75

pharmaphorum

JANUARY 16, 2023

Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. Alzheimer’s is currently the seventh-leading cause of death globally and growing fast.

FDA 82

FDA Healthcare Healthcare Medicine 82

European Pharmaceutical Review

DECEMBER 11, 2023

Based on learnings from ASOs and siRNAs they also leverage unique engineering and drug delivery techniques that enable them to target a broader set of cell types, including many that have been previously untreatable with RNA therapeutics. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging.

Pharmacology 81

Pharmacology Safety Engineering Medical 81

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 75

Food and Drug Administration Safety Patients Leads 75